Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for ...

Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus ...

Merck (NYSE:MRK) reported multiple positive Phase 3 results for KEYTRUDA-based combinations in renal cell carcinoma, bladder ...

A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...

Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...

Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales ...

Gemcitabine intravesical system+intravenous cetrelimab did not improve bladder-intact event-free survival or OS for pts with ...

Findings presented at the 2026 ASCO GU Symposium show that combinatorial therapies may provide new treatment options for ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for ...

US pharma giant Pfizer has withdrawn its European application for a marketing authorization of Zumrad (sasanlimab) for the ...

The phase 3 IMvigor011 (NCT04660344) 1 trial, presented at the 2026 American Society of Clinical Oncology Genitourinary ...